© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
The Melanoma Research Alliance presents a Perspective in Cancer Cell, which identifies challenges in melanoma research and drug discovery
Researchers report that a personalized cancer vaccine called NeoVax may work to keep melanoma at bay
Altering gut bacteria may help overcome resistance to checkpoint inhibitors in people with melanoma and other cancers.
Nearly four years after vaccination, patients’ immune cells were still active against their cancer.
Mitch Diamond, 13, is asking others to help him raise awareness of and help prevent melanoma in honor of his late grandfather.
The Melanoma Research Alliance shares the top five items that has our team excited for the coming year in the fight against melanoma.
A new paper calls for a halt to skin cancer screenings in the general population. Some physicians vehemently disagree.
Barbara Premisler uses art to process her feelings and briefly escape the pressures and stress of her metastatic melanoma diagnosis.
The technology used in COVID-19 vaccines may also be used to prevent other viral infections and to treat cancer and multiple sclerosis.
The decrease is largely due to improved lung cancer treatment, but the impact of COVID-19 is not yet known.
The American Academy of Dermatology designates the first Monday in May as Melanoma Monday.
Scientists assembled the largest molecular dataset and used it to uncover new details that may help in diagnosis and treatment.
Mary Jo Rogers discusses her experience with cancer treatment after her 2011 diagnosis of Stage 3C melanoma.
Researchers at the annual Society for the Immunotherapy for Cancer reported on melanoma clinical trial results from this year.
Artificial intelligence may help predict response to immune checkpoint blockade in patients with metastatic melanoma
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.